|Articles|July 18, 2008

FDA recalls two lots of drug to treat hyperkalemia

A sample of one affected lot tested positive for a strain of yeast.

The U.S. Food & Drug Administration has recalled two lots of Roxane Laboratories, Inc.'s Sodium Polystyrene Sulfonate Suspension, USP, 15 g/60 mL Unit dose bottles (NDC 0054-0165-51; lot 856396A Exp April 2010, and lot 856693A Exp May 2010), a product used to treat hyperkalemia. A sample of one affected lot tested positive for a strain of yeast, which may affect immunocompromised patients.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, .

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Related to this article

Postmenopausal Women, GLP-1 Therapy, Muscle Loss, Sarcopenia

September 25th, 2026

Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women

With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.

September 25th, 2026

Menopause Status, Symptoms Remain Inconsistently Documented

Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.

Main Street Pharmacy Access Act, Pharmacist Provider Status, Test-and-Treat Services, Medicare Part B, Social Security Act

September 24th, 2026

The Legislation Setting the Stage for Pharmacy’s Next Leap

As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.

September 24th, 2026

Study Finds Reduced Cardiovascular Risk With Hormone Therapy Initiation

Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.